Page 116 - 《中国药房》2023年17期
P. 116

·循证药学·


          不同剂量锌治疗儿童腹泻有效性和安全性的系统评价
                                                                                             Δ

                                                                   2
                                   1
                                                   1
                                           1
                                                                            1 #
                           1
                 1*
                                                           1
          涂彩霞 ,任丹阳 ,李云巍 ,杨琰茗 ,沈建玲 ,刘 艳 ,刘 婷 ,李惠英 (1.昆明市儿童医院/昆明医科大学附
          属儿童医院药剂科,昆明 650228;2.昆明医科大学药学院,昆明 650500)
          中图分类号  R969.3      文献标志码  A      文章编号  1001-0408(2023)17-2154-08
          DOI  10.6039/j.issn.1001-0408.2023.17.19
          摘   要  目的  探讨不同剂量锌治疗儿童腹泻的有效性和安全性,为临床合理用药提供参考。方法  计算机检索 PubMed、Co‐
          chrane Library、Embase数据库中有关锌(锌组)对比安慰剂和或常规治疗等(对照组)治疗儿童腹泻的随机对照试验(RCT),检索
          时限为建库起至2022年10月,参考Cochrane Handbook 6.0对纳入的文献进行质量评价,并采用RevMan 5.3软件进行Meta分析和
          敏感性分析。结果  最终纳入25项RCT,共8 618例患儿。Meta分析结果显示,在腹泻持续时间方面,锌元素<20 mg组中,锌组
          患儿腹泻持续时间显著短于对照组[SMD=-0.39,95%CI(-0.71,-0.08),P=0.01],但在年龄<6个月的亚组中,两组间差异无
          统计学意义[SMD=0.01,95%CI(-0.10,0.11),P=0.88];锌元素 20 mg 组中,锌组患儿腹泻持续时间显著短于对照组[SMD=
          -0.52,95%CI(-0.80,-0.23),P=0.000 3];锌元素>20 mg组中,锌组患儿腹泻持续时间显著短于对照组[SMD=-0.83,95%CI
         (-1.39,-0.27),P=0.004];年龄≤12个月时锌>10 mg或年龄>12个月时锌>20 mg组(简称“等剂量组”)中,锌组患儿腹泻持
          续时间显著短于对照组[SMD=-0.16,95%CI(-0.27,-0.06),P=0.003]。在治疗7 d后腹泻率方面,锌组和对照组治疗7 d后腹
          泻率的差异均无统计学意义:锌元素<20 mg组[OR=1.28,95%CI(0.96,1.70),P=0.09],锌元素20 mg组[OR=0.40,95%CI(0.15,
          1.01),P=0.05],等剂量组[OR=0.64,95%CI(0.28,1.44),P=0.28]。在呕吐率方面,锌元素<20 mg组中,锌组患儿呕吐率显著高
          于对照组[OR=2.13,95%CI(1.68,2.70),P<0.001];等剂量组中,锌组患儿呕吐率显著高于对照组[OR=1.84,95%CI(1.44,2.34),
          P<0.001];锌元素 20 mg 组和>20 mg 组中,锌组和对照组患儿呕吐率的差异无统计学意义(P>0.05)。敏感性分析结果均无翻
          转。结论  锌可显著缩短患儿(6个月及以上)腹泻持续时间,但低剂量(<20 mg)就有增加呕吐的风险,临床应予以重视。
          关键词  锌;剂量;腹泻;腹泻持续时间;呕吐;Meta分析

          Efficacy and safety of different doses of zinc in the treatment of diarrhea in children: a systematic review
                                                              1
                                  1
          TU Caixia ,REN Danyang ,LI Yunwei ,YANG Yanming ,SHEN Jianling ,LIU Yan ,LIU Ting ,LI Huiying      1
                                             1
                                                                                       1
                                                                                                 2
                   1
                                                                             1
         (1.  Dept.  of  Pharmacy,  Kunming  Children’s  Hospital/the  Affiliated  Children’s  Hospital  of  Kunming  Medical
          University, Kunming 650228, China;2. School of Pharmacy, Kunming Medical University, Kunming 650500,
          China)
          ABSTRACT    OBJECTIVE  To  investigate  the  efficacy  and  safety  of  different  doses  of  zinc  in  the  treatment  of  diarrhea  in
          children,  and  to  provide  a  reference  for  clinical  safe  and  rational  drug  use.  METHODS  Retrieved  from  PubMed,  Cochrane
          Library,  Embase  database,  randomized  controlled  trials  about  zinc (zinc  group)  versus  placebo  or  conventional  treatment (control
          group) in the treatment of diarrhea in children were collected from the inception to October 2022. Then, the quality of the included
          literature was evaluated by the Cochrane Handbook 6.0, and meta-analysis and sensitivity analysis were performed by RevMan 5.3
          software.  RESULTS  Finally,  25  RCTs  were  included,  with  a  total  of  8  618  children. The  results  of  meta-analysis  showed  that  in
          terms  of  duration  of  diarrhea,  in  zinc  <20  mg  group,  the  zinc  group  was  significantly  shorter  than  the  control  group  [SMD=
          -0.39, 95%CI(-0.71, -0.08), P=0.01], but in subgroups of <6 months old, there was no significant difference between the
          two groups [SMD=0.01, 95%CI(-0.10, 0.11), P=0.88]. In zinc 20 mg group, the zinc group was significantly shorter than the
          control  group  [SMD=-0.52,  95%CI(-0.80,  -0.23),  P=0.000  3].  In  zinc  >20  mg  group,  the  zinc  group  was  significantly
          shorter than the control group [SMD=-0.83, 95%CI(-1.39, -0.27), P=0.004]. In zinc >10 mg (age ≤12 months) or zinc >
                                                              20  mg (age  >12  months)  group (short  for “constant  dose
              Δ 基金项目 云南省卫生科技计划项目(No.2018NS0174);昆明市           group”),  the  zinc  group  was  significantly  shorter  than  the
          卫生科技人才培养项目[No.2023-SW(技)-19]
                                                              control  group  [SMD=-0.16,  95%CI(-0.27,  -0.06),  P=
             *第一作者 主管药师,硕士。研究方向:临床药学、循证药学、药
                                                              0.003]. In the aspect of diarrhea rate after 7 days of treatment,
          品临床综合评价。E-mail:Tu_caixia@163.com
              # 通信作者 主任药师,硕士。研究方向:临床药学、药事管理。                  there  was  no  significant  difference  in  the  diarrhea  rate  after  7
          E-mail:lihuiying@etyy.cn                            days  of  treatment  between  the  zinc  group  and  the  control


          · 2154 ·    China Pharmacy  2023 Vol. 34  No. 17                            中国药房  2023年第34卷第17期
   111   112   113   114   115   116   117   118   119   120   121